Summary: In previous research, Dana-Farber researchers found that a tumor’s genomic heterogeneity, meaning the tumor’s propensity to develop new mutations, and low genomic ploidy, a measure of the number of chromosomes in the cells, predicts resistance to immune checkpoint blockade with anti-PD-1 therapy.
Of Interest
HBI-8000 Plus Nivolumab Is Safe, Active in Melanoma
The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no prior anti–PD-1/PD-L1 treatment.
Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma
The FDA received a biologics license application for the accelerated approval of RP1 (vusolimogene oderparepvec) plus nivolumab (Opdivo) to treat adults with with advanced melanoma that was previously treated with a PD1 inhibitor.
Unexpected Findings in Study of T Cells, Considered Front-line Fighters Against Advanced Melanoma
Yale researchers made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma that was published Nov. 28 in Nature Immunology.